EDGEWISE THERAPEUTICS INC (EWTX)
Health Care · Biotechnology · NASDAQ
A clinical-stage biopharmaceutical company developing oral, precision small molecule medicines for the treatment of serious cardiovascular diseases.
What EDGEWISE THERAPEUTICS INC does
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule precision medicines for severe cardiovascular diseases. The company utilizes a proprietary drug discovery platform to develop oral, selective cardiac sarcomere modulators. Its pipeline is led by EDG-7500, which is in late-stage clinical trials for hypertrophic cardiomyopathy, and EDG-15400, targeting heart failure with preserved ejection fraction.
Themes: cardiovascular diseases, hypertrophic cardiomyopathy (HCM), heart failure with preserved ejection fraction (HFpEF), precision medicine
Fundamentals
- Price$39.65 as of 2026-10-21 close
- Market cap$4.3B as of 2026-07-31 (share count; price 2026-10-21)
- 1-year return+155.6% 2025-10-21 close $15.51 → 2026-10-21 close $39.65
- P/En/a negative earnings
- ROE-32.1% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta1.16 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How EWTX compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
EWTX is not currently in any published Top 10 list. Its scores are below.
Top 10 score
Not scored for the top 10 list: no growth data.
Scores as of 21 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$62M | -$57M | -$0.53 | -$42M† | $32000† |
| Q1 FY2026 2026-03-31 | -$54M | -$49M | -$0.46 | -$43M | $260000 |
| Q4 FY2025 2025-12-31 | -$56M† | -$50M† | -$0.48† | -$39M† | $73000† |
| Q3 FY2025 2025-09-30 | -$47M | -$41M | -$0.39 | -$35M† | $89000† |
| Q2 FY2025 2025-06-30 | -$43M | -$36M | -$0.34 | -$33M† | $50000† |
| Q1 FY2025 2025-03-31 | -$46M | -$41M | -$0.43 | -$38M | $44000 |
| Q4 FY2024 2024-12-31 | -$46M† | -$40M† | -$0.42† | -$27M† | $274000† |
| Q3 FY2024 2024-09-30 | -$40M | -$34M | -$0.36 | -$27M† | $520000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$72M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How EDGEWISE THERAPEUTICS INC looks technically
EDGEWISE THERAPEUTICS INC (EWTX) is trading 11.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 225 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It made a new 20-day low about 7 trading days ago. It is 18.3% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 11.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +11.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $41.99 | $41.99 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $35.61 | $35.61 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 225 trading days ago — a "golden cross", a bullish long-term signal | 225 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend) | 17.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30) | 48.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($35.63 to $41.94) — its "stochastic" reading is 64 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 63.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $48.51 | $48.51 |
|---|---|---|
| From the 52-week high | it is 18.3% below its 52-week high (its highest price of the past year) | -18.3% |
| Above the 52-week low | it is 170.2% above its 52-week low (its lowest price of the past year) | +170.2% |
| Below the 52-week high | it is 18.3% below its highest point of the past year | 18.3% |
| Since a 20-day breakout | it made a new 20-day low about 7 trading days ago | 7 sessions |
| Since a 55-day breakout | it made a new 55-day low about 7 trading days ago | 7 sessions |
| All-time high | its highest closing price on record is $48.51 (set on 2026-09-17) | $48.51 |
| Given back of the 52-week move | over the past year its closes ranged ($14.89 to $48.35), and it has given back roughly a quarter of its rise from last year’s low — 26% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $26.60 to $27.67. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 26.0% |
| From the all-time high | it is 18.3% below its all-time high | -18.3% |
| Nearest price level | it is trading 2.6% below a resistance level at $40.70 — a price it turned at twice since 2026-06-01, most recently on 2026-08-31. Since 2024-10-21 it has 14 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.6% |
| All-time low | its lowest closing price on record is $5.12 (set on 2023-11-10) | $5.12 |
| Above the all-time low | it is 674.4% above its all-time low | +674.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 81% of it) | 19th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.93 between its high and its low — about 4.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.93 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $36.56 and $41.90 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $36.56 – $39.23 – $41.90 |
| Typical daily range (% of price) | its price moves about 4.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.9% |
| Stretch from the 200-day average | it is trading 2.1 daily ranges above its 200-day average price (11.4% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.10× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bearish engulfing | 3 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 3 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.5% |
|---|---|---|
| Gap filled | a 3.6% gap down opened on 2026-10-08 has been "filled" 8 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 8 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 11.1 percentage points (the stock lost 11.2% while the market lost 0.1%) | -11.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 3.1 percentage points (the stock gained 0.2% while the market gained 3.3%) | -3.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 12.4 percentage points (the stock gained 22.2% while the market gained 9.8%) | +12.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 140.5 percentage points (the stock gained 155.6% while the market gained 15.2%) | +140.5% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.0% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 2.0% of the share price, which is taken to mean a barrier that gives way easily. | -7.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $36.74 — a volume-weighted average of daily closes over 199 sessions, not a true tick-by-tick VWAP. | +7.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $42.08 — a volume-weighted average of daily closes over 54 sessions, not a true tick-by-tick VWAP. | -5.8% |
Double top, bearish — broke down · entry $41.77 · 44 sessions in
Price levels it has turned at before
EWTX last closed at $39.65 on 2026-10-21. Since 2024-10-21 it has turned at 14 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $40.70 | Resistance | 2.6% above the last close | turned there twice · 2026-06-01 to 2026-08-31 |
| $38.33 | Support | 3.3% below the last close | turned there three times · 2024-11-11 to 2026-09-29 |
| $42.18 | Resistance | 6.4% above the last close | turned there twice · 2026-07-27 to 2026-08-14 |
| $37.06 | Support | 6.5% below the last close | turned there twice · 2026-07-17 to 2026-08-03 |
| $35.38 | Support | 10.8% below the last close | turned there three times · 2024-12-16 to 2026-10-14 |
| $46.26 | Resistance | 16.7% above the last close | turned there twice · 2026-08-05 to 2026-08-19 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading below the 50-day moving average · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · beating the market · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.54 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$52.62 range $36.00 – $66.00; median $53.00
Analyst estimates, as of 2026-10-15. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for EWTX
- Consensus EPS estimate$2.81 next reporting period, as of 2026-10-15
- Estimate change, 30 days$0.00 (0.0%) from $2.81, on 2026-09-10, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant history of operating losses and an accumulated deficit.","Dependence on the successful development and regulatory approval of clinical-stage product candidates.","Risks related to macroeconomic and geopolitical developments impacting clinical trials and capital markets."]
What changed in the latest 10-Q
AI-assisted comparison of EWTX's 10-Q filed 2026-08-06 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (filed 2026-08-06) adds description of Asset Purchase Agreement with Servier Pharmaceuticals LLC and Les Laboratoires Servier acquiring sevasemten and the muscular dystrophy program for $1,550 million upfront cash, up to $1,100 million in additional regulatory and commercial milestone payments, for aggregate potential consideration of up to $2,650 million (Sevasemten Sale), completed July 10, 2026.
- Newer filing (filed 2026-08-06) adds statement that following the Sevasemten Sale, Edgewise is positioned as a cardiovascular-focused late-stage clinical biopharmaceutical company.
- Newer filing (filed 2026-08-06) adds Phase 3 program for EDG-7500 targeted to initiate in the fourth quarter of 2026.
- Newer filing (filed 2026-08-06) adds net loss figures for the three and six months ended June 30, 2026 ($57.3 million and $106.3 million, respectively) and for the three and six months ended June 30, 2025 ($36.1 million and $76.9 million, respectively).
- Newer filing (filed 2026-08-06) adds $1,550 million in upfront cash proceeds from the Sevasemten Sale received on July 10, 2026, to the cash position discussion.
- Removed:
- Older filing (filed 2026-05-07) contains description of sevasemten as an orally administered selective, fast myofiber (type II) myosin small molecule inhibitor studied in late-stage clinical trials in Becker and Duchenne muscular dystrophy, including an ongoing pivotal cohort trial in Becker, removed in newer filing.
- Older filing (filed 2026-05-07) contains the mission statement referring to changing the lives of patients and families affected by serious muscle diseases, replaced in newer filing.
- Older filing (filed 2026-05-07) contains paragraphs describing the company as a late-stage clinical biopharmaceutical company focused on muscle diseases, the holistic drug discovery approach, and the proprietary muscle focused drug discovery platform, removed in newer filing.
- Older filing (filed 2026-05-07) contains net loss figures for the three months ended March 31, 2026 and 2025 ($49.0 million and $40.8 million, respectively), removed in newer filing.
- Older filing (filed 2026-05-07) contains accumulated deficit of $595.4 million as of March 31, 2026, removed in newer filing.
- Older filing (filed 2026-05-07) contains cash and cash equivalents and marketable securities of $499.6 million as of March 31, 2026, removed in newer filing.
- Reworded:
- Newer filing (filed 2026-08-06) describes the company's foundation as a proprietary precision medicine platform generating multiple clinical and preclinical programs across skeletal and cardiac muscle; older filing (filed 2026-05-07) describes a precision medicine muscle platform generating programs for muscle diseases.
- Newer filing (filed 2026-08-06) describes sevasemten as previously in the muscular dystrophy program sold to Servier; older filing (filed 2026-05-07) describes sevasemten as an active muscular dystrophy program candidate.
- Newer filing (filed 2026-08-06) describes the mission as changing the lives of patients and families affected by serious cardiovascular diseases; older filing (filed 2026-05-07) describes the mission as changing the lives of patients and families affected by serious muscle diseases.
- Newer filing (filed 2026-08-06) states preclinical discovery efforts include additional cardiovascular and cardiometabolic targets; older filing (filed 2026-05-07) states preclinical exploration includes novel cardiometabolic targets.
- Newer filing (filed 2026-08-06) updates accumulated deficit to $652.7 million as of June 30, 2026; older filing (filed 2026-05-07) states $595.4 million as of March 31, 2026.
- Newer filing (filed 2026-08-06) updates cash and cash equivalents and marketable securities to $460.7 million as of June 30, 2026; older filing (filed 2026-05-07) states $499.6 million as of March 31, 2026.
- Newer filing (filed 2026-08-06) states research and development expenses have been incurred mostly to advance lead product candidate EDG-7500, as well as sevasemten, previous product candidate sold to Servier; older filing (filed 2026-05-07) states expenses have been incurred mostly to advance lead product candidates sevasemten and EDG-7500.
- Newer filing (filed 2026-08-06) states expected significant additional spending for EDG-7500, EDG-15400, and other potential discoveries; older filing (filed 2026-05-07) states expected significant additional spending for these, EDG-15400, and other potential discoveries.
- Notes:
- The newer filing source text appears truncated mid-sentence in the Research and development expenses section ('once a lead com'), so later portions of the MD&A were not available for comparison.
- Comparison is limited to the extracted text provided; changes beyond the extracted portions are not assessed.
Risk Factors
- Removed:
- In the Risk Factors Summary under "Risks Related to the Discovery, Development and Commercialization of Our Product Candidates", the older filing (filed 2026-05-07) included a bullet: "We may develop sevasemten and potentially other programs in combination with other therapies, which would expose us to additional risks." This bullet is absent from the newer filing (filed 2026-08-06).
- In the Risk Factors Summary under "Risks Related to the Discovery, Development and Commercialization of Our Product Candidates", the older filing (filed 2026-05-07) included a bullet: "The patient population suffering from Duchenne muscular dystrophy (Duchenne), Becker muscular dystrophy (Becker) and Limb-girdle muscular dystrophy (LGMD) is small and has not been established with precision. If the actual number of patients is smaller than we estimate, our revenue and ability to achieve profitability may be adversely affected. Because the target patient populations of our programs are small and the addressable patient population may be even smaller, we must be able to successfully identify patients and capture a significant market share to achieve profitability and growth." This bullet is absent from the newer filing (filed 2026-08-06).
- Reworded:
- The older filing (filed 2026-05-07) stated: "We will require substantial additional capital to finance our operations..." The newer filing (filed 2026-08-06) changed this to: "We may require substantial additional capital to finance our operations..."
- The older filing (filed 2026-05-07) stated: "We are substantially dependent on the success of our lead product candidates, sevasemten and EDG-7500. If we are unable to complete further development of, obtain approval for and commercialize sevasemten or EDG-7500 for one or more indications in a timely manner, our business will be harmed." The newer filing (filed 2026-08-06) changed this to: "We are substantially dependent on the success of our lead product candidate EDG-7500. If we are unable to complete further development of, obtain approval for and commercialize EDG-7500 for one or more indications in a timely manner, our business will be harmed." (i.e., removed reference to sevasemten)
- The older filing (filed 2026-05-07) stated: "In addition to sevasemten and EDG-7500, our prospects depend in part upon developing and commercializing EDG-15400..." The newer filing (filed 2026-08-06) changed this to: "In addition to EDG-7500, our prospects depend in part upon developing and commercializing EDG-15400..." (i.e., removed reference to sevasemten)
- The older filing (filed 2026-05-07) stated: "We have limited resources and are currently focusing the majority of our efforts on developing sevasemten and EDG-7500 for particular indications." The newer filing (filed 2026-08-06) changed this to: "We have limited resources and are currently focusing the majority of our efforts on developing EDG-7500 for particular indications." (i.e., removed reference to sevasemten)
- Notes:
- The newer filing text appears to be cut off mid-sentence at the end of the excerpt ("...which increases the possibility that a competitor will discover them or tha"), and the older filing text appears to be cut off at the end of the excerpt as well. Changes after these truncation points cannot be assessed.
- Page numbers differ between the two filings (newer: pages 30-31; older: pages 27-28), reflecting layout changes rather than substantive changes to the risk factor content.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 19 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 6 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-160 buys · 19 sells ($2M) — 5 selling insiders
- Last 180 days · read to 2026-10-160 buys · 23 sells ($12M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-13. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about EWTX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding EWTX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 14,985,012
- Reported value $608,841,039
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about EWTX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
EWTX had 11,224,347 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
EWTX had 10.3% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.6 days to cover at the same settlement.
- Reported short interest (shares) 11,224,347
- Short interest (% of shares outstanding) 10.3%
- Prior settlement (shares) 9,543,843
- Reported change 17.61%
- Days to cover (reported) 5.6
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare EWTX vs…
EDGEWISE THERAPEUTICS INC is found in…
Frequently asked questions
What does EDGEWISE THERAPEUTICS INC (EWTX) do?
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule precision medicines for severe cardiovascular diseases. The company utilizes a proprietary drug discovery platform to develop oral, selective cardiac sarcomere modulators. Its pipeline is led by EDG-7500, which is in late-stage clinical trials for hypertrophic cardiomyopathy, and EDG-15400, targeting heart failure with preserved ejection fraction.
What sector is EDGEWISE THERAPEUTICS INC (EWTX) in?
EDGEWISE THERAPEUTICS INC (EWTX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are EDGEWISE THERAPEUTICS INC's (EWTX) competitors?
Notable peers of EDGEWISE THERAPEUTICS INC (EWTX) include Bristol Myers Squibb and Cytokinetics. This peer set is informational only — not financial advice.
Is EDGEWISE THERAPEUTICS INC (EWTX) overbought or oversold right now?
EDGEWISE THERAPEUTICS INC (EWTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 49, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on EWTX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.